期刊
BRITISH JOURNAL OF CANCER
卷 119, 期 6, 页码 693-696出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41416-018-0251-2
关键词
-
类别
资金
- Cure Brain Cancer Foundation
- Australian Lions Childhood Cancer Research Foundation
- Lions Club International Foundation (LCIF)
- CRC for Cancer Therapeutics
- Kids Cancer Project
- Cancer Institute NSW
- NSW Department of Health
- Commonwealth Government of Australia
- NSW State Government
- University of NSW
- Tour de Cure
- Rich Family Foundation
- Robert Connor Dawes Foundation
- Lenity Foundation
Genes encoding TRK are oncogenic drivers in multiple tumour types including infantile fibrosarcoma, papillary thyroid cancer and high-grade gliomas (HGG). TRK fusions have a critical role in tumourigenesis in 40% of infant HGG. Here we report the first case of a TRK fusion-driven HGG treated with larotrectinib-the first selective pan-TRK inhibitor in clinical development. This 3-year-old girl had failed multiple therapies including chemotherapy and radiotherapy. Tumour profiling confirmed an ETV6-NTRK3 fusion. Treatment with larotrectinib led to rapid clinical improvement with near total resolution of primary and metastatic lesions on MRI imaging. This is the first report of a TRK fusion glioma successfully treated with a TRK inhibitor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据